Nureca Limited (NURECA) — Annual Report
Nureca Limited's FY26 annual report shows revenue growth of 34% to ₹1,469.93 crores, EBITDA up 68.94% to [amount context mismatch] crores, and PAT surging 146.10% to [amount context mismatch] crores, driven by strong domestic demand and operational improvements. The company appointed Ms. Smita Goyal as Whole-time Director effective June 1, 2026, while CEO Mr. Aryan Goyal will resign on July 1, 2026. Board composition remains stable with 5 independent directors out of 8 total, and the merger with Nureca Technologies is shareholder-approved. Key risks include foreign exchange volatility, regulatory changes, and intense competition in India's healthcare market, though the company maintains a healthy current ratio of 25 and ROCE of 521%.
About Nureca Limited (NURECA)
Healthcare · Healthcare Equipment & Supplies · Listed on NSE
📡 Get AI alerts when NURECA files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track NURECA — Free💡 Ask AI about this filing
📊 More NURECA filings
- 🟡 Board Meeting — 21 July 2026 Nureca Limited announced the unaudited standalone and consolidated financial results for Q1 FY26-27 ...
- 🔴 Financial Results — 21 July 2026 Nureca reported Q1 FY27 revenue of **₹40.3 crores**, up 14% QoQ and 18% YoY, driven by strong gross ...
- share transfer — 15 July 2026 Nureca Limited received a SEBI-mandated share transfer agent certificate for the quarter ended June ...
- Announcement — 1 July 2026 Nureca Limited announced the resignation of Whole-time Director and CEO Aryan Goyal effective close ...
- 🟡 Board Meeting — 1 July 2026 No summary available
🔥 Also filed on 3 July 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when NURECA files new disclosures
Track NURECA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track NURECA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research